Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report released on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Stock Up 2.6 %

Shares of Cyclacel Pharmaceuticals stock opened at $0.30 on Friday. The firm has a market cap of $1.92 million, a PE ratio of -0.03 and a beta of 0.28. Cyclacel Pharmaceuticals has a twelve month low of $0.29 and a twelve month high of $4.00. The business has a 50-day moving average price of $0.35 and a 200 day moving average price of $0.56.

Insider Buying and Selling at Cyclacel Pharmaceuticals

In related news, CEO David E. Lazar sold 194,628,820 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total value of $5,838,864.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 23.97% of the stock is currently owned by insiders.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.